On Monday, Prelude Therapeutics Inc (NASDAQ: PRLD) was 8.55% up from the session before settling in for the closing price of $1.52. A 52-week range for PRLD has been $0.61 – $4.22.
Healthcare Sector giant saw their annual sales slid by -21.61% over the last five years. When this article was written, the company’s average yearly earnings per share was at 20.44%. With a float of $20.76 million, this company’s outstanding shares have now reached $43.75 million.
Prelude Therapeutics Inc (PRLD) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Prelude Therapeutics Inc stocks. The insider ownership of Prelude Therapeutics Inc is 63.31%, while institutional ownership is 28.77%. The most recent insider transaction that took place on Mar 25 ’25, was worth 69,250. In this transaction Chief Chemistry Officer of this company bought 100,000 shares at a rate of $0.69, taking the stock ownership to the 480,123 shares. Before that another transaction happened on Mar 25 ’25, when Company’s CEO bought 675,000 for $0.69, making the entire transaction worth $467,438. This insider now owns 1,999,296 shares in total.
Prelude Therapeutics Inc (PRLD) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.37 earnings per share (EPS) during the time that was better than consensus figure (set at -0.47) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.46% during the next five years compared to -21.61% drop over the previous five years of trading.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
You can see what Prelude Therapeutics Inc (PRLD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Analysing the last 5-days average volume posted by the [Prelude Therapeutics Inc, PRLD], we can find that recorded value of 0.68 million was better than the volume posted last year of 0.52 million. As of the previous 9 days, the stock’s Stochastic %D was 45.70%.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 25.94%, which indicates a significant increase from 15.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.3872 in the past 14 days, which was higher than the 0.1643 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4125, while its 200-day Moving Average is $1.0134. Now, the first resistance to watch is $1.7400. This is followed by the second major resistance level at $1.8300. The third major resistance level sits at $1.9700. If the price goes on to break the first support level at $1.5100, it is likely to go to the next support level at $1.3700. Should the price break the second support level, the third support level stands at $1.2800.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
There are 62,865K outstanding shares of the company, which has a market capitalization of 124.93 million. As of now, sales total 7,000 K while income totals -127,170 K. Its latest quarter income was 0 K while its last quarter net income were -32,090 K.
